Mobile application-based Seoul National University Prostate Cancer Risk Calculator: development, validation, and comparative analysis with two Western risk calculators in Korean men
- PMID: 24710020
- PMCID: PMC3978062
- DOI: 10.1371/journal.pone.0094441
Mobile application-based Seoul National University Prostate Cancer Risk Calculator: development, validation, and comparative analysis with two Western risk calculators in Korean men
Abstract
Objectives: We developed a mobile application-based Seoul National University Prostate Cancer Risk Calculator (SNUPC-RC) that predicts the probability of prostate cancer (PC) at the initial prostate biopsy in a Korean cohort. Additionally, the application was validated and subjected to head-to-head comparisons with internet-based Western risk calculators in a validation cohort. Here, we describe its development and validation.
Patients and methods: As a retrospective study, consecutive men who underwent initial prostate biopsy with more than 12 cores at a tertiary center were included. In the development stage, 3,482 cases from May 2003 through November 2010 were analyzed. Clinical variables were evaluated, and the final prediction model was developed using the logistic regression model. In the validation stage, 1,112 cases from December 2010 through June 2012 were used. SNUPC-RC was compared with the European Randomized Study of Screening for PC Risk Calculator (ERSPC-RC) and the Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC). The predictive accuracy was assessed using the area under the receiver operating characteristic curve (AUC). The clinical value was evaluated using decision curve analysis.
Results: PC was diagnosed in 1,240 (35.6%) and 417 (37.5%) men in the development and validation cohorts, respectively. Age, prostate-specific antigen level, prostate size, and abnormality on digital rectal examination or transrectal ultrasonography were significant factors of PC and were included in the final model. The predictive accuracy in the development cohort was 0.786. In the validation cohort, AUC was significantly higher for the SNUPC-RC (0.811) than for ERSPC-RC (0.768, p<0.001) and PCPT-RC (0.704, p<0.001). Decision curve analysis also showed higher net benefits with SNUPC-RC than with the other calculators.
Conclusions: SNUPC-RC has a higher predictive accuracy and clinical benefit than Western risk calculators. Furthermore, it is easy to use because it is available as a mobile application for smart devices.
Conflict of interest statement
Figures





Similar articles
-
Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review.JMIR Cancer. 2021 Sep 3;7(3):e30430. doi: 10.2196/30430. JMIR Cancer. 2021. PMID: 34477564 Free PMC article. Review.
-
European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.BJU Int. 2016 Nov;118(5):706-713. doi: 10.1111/bju.13437. Epub 2016 Feb 29. BJU Int. 2016. PMID: 26833820 Clinical Trial.
-
Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.BJU Int. 2016 Mar;117(3):401-8. doi: 10.1111/bju.13314. Epub 2015 Oct 5. BJU Int. 2016. PMID: 26332503 Clinical Trial.
-
Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.Eur Urol. 2012 Mar;61(3):577-83. doi: 10.1016/j.eururo.2011.11.012. Epub 2011 Nov 15. Eur Urol. 2012. PMID: 22104592
-
Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?Yonsei Med J. 2013 May 1;54(3):665-71. doi: 10.3349/ymj.2013.54.3.665. Yonsei Med J. 2013. PMID: 23549812 Free PMC article.
Cited by
-
Natural history of incidentally diagnosed prostate cancer after holmium laser enucleation of the prostate.PLoS One. 2023 Feb 2;18(2):e0278931. doi: 10.1371/journal.pone.0278931. eCollection 2023. PLoS One. 2023. PMID: 36730281 Free PMC article.
-
Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App.JMIR Cancer. 2017 Jan 6;3(1):e1. doi: 10.2196/cancer.6750. JMIR Cancer. 2017. PMID: 28410180 Free PMC article.
-
Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.PLoS One. 2017 Jan 3;12(1):e0168917. doi: 10.1371/journal.pone.0168917. eCollection 2017. PLoS One. 2017. PMID: 28046017 Free PMC article.
-
Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.Res Sq [Preprint]. 2025 Jul 4:rs.3.rs-6905600. doi: 10.21203/rs.3.rs-6905600/v1. Res Sq. 2025. PMID: 40630527 Free PMC article. Preprint.
-
Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review.JMIR Cancer. 2021 Sep 3;7(3):e30430. doi: 10.2196/30430. JMIR Cancer. 2021. PMID: 34477564 Free PMC article. Review.
References
-
- Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, et al (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61: 1079–1092. - PubMed
-
- Batura D, Gopal Rao G (2013) The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J Antimicrob Chemother 68: 247–249. - PubMed
-
- Kibel AS (2013) To biopsy or not to biopsy: minimizing the risk of prostate needle biopsy. J Urol 189: 796–797. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials